+

WO2004013166A3 - S. aureus antigene - Google Patents

S. aureus antigene Download PDF

Info

Publication number
WO2004013166A3
WO2004013166A3 PCT/EP2003/007955 EP0307955W WO2004013166A3 WO 2004013166 A3 WO2004013166 A3 WO 2004013166A3 EP 0307955 W EP0307955 W EP 0307955W WO 2004013166 A3 WO2004013166 A3 WO 2004013166A3
Authority
WO
WIPO (PCT)
Prior art keywords
aureus
antigene
vaccine
seq
nos
Prior art date
Application number
PCT/EP2003/007955
Other languages
French (fr)
Other versions
WO2004013166A2 (en
Inventor
Ahsen Uwe Von
Johannes Soellner
Thomas Weichhart
Martin Hafner
Original Assignee
Intercell Ag
Ahsen Uwe
Johannes Soellner
Thomas Weichhart
Martin Hafner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag, Ahsen Uwe, Johannes Soellner, Thomas Weichhart, Martin Hafner filed Critical Intercell Ag
Priority to AU2003254555A priority Critical patent/AU2003254555A1/en
Publication of WO2004013166A2 publication Critical patent/WO2004013166A2/en
Publication of WO2004013166A3 publication Critical patent/WO2004013166A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Described are novel antigens from S. aureus selected from the group consisting of Seq.ID.Nos. 7 to 12, as well as their use in a pharmaceutical preparation, especially in a vaccine.
PCT/EP2003/007955 2002-07-26 2003-07-22 S. aureus antigene WO2004013166A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003254555A AU2003254555A1 (en) 2002-07-26 2003-07-22 S. aureus antigene

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA1146/2002 2002-07-26
AT11462002 2002-07-26

Publications (2)

Publication Number Publication Date
WO2004013166A2 WO2004013166A2 (en) 2004-02-12
WO2004013166A3 true WO2004013166A3 (en) 2004-04-08

Family

ID=31192773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/007955 WO2004013166A2 (en) 2002-07-26 2003-07-22 S. aureus antigene

Country Status (2)

Country Link
AU (1) AU2003254555A1 (en)
WO (1) WO2004013166A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
AU2006206577B2 (en) * 2005-01-21 2012-03-08 Merck Sharp & Dohme Corp. Polypeptides for inducing a protective immune response against Staphylococcus aureus
BRPI0607323B8 (en) 2005-02-14 2021-05-25 Epitopix Llc compositions, uses of polypeptides and antibodies, as well as kits for detecting antibody that specifically binds to a polypeptide
US9932373B2 (en) 2009-03-23 2018-04-03 Epitopix, Llc Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011184A1 (en) * 1998-08-25 2000-03-02 Schering Corporation Staphylococcus aureus polypeptides
WO2000045839A2 (en) * 1999-02-01 2000-08-10 Cistem Biotechnologies Gmbh A method for selecting and producing vaccine and diagnostic preparations
WO2001098499A1 (en) * 2000-06-20 2001-12-27 University Of Sheffield Antigenic polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000011184A1 (en) * 1998-08-25 2000-03-02 Schering Corporation Staphylococcus aureus polypeptides
WO2000045839A2 (en) * 1999-02-01 2000-08-10 Cistem Biotechnologies Gmbh A method for selecting and producing vaccine and diagnostic preparations
WO2001098499A1 (en) * 2000-06-20 2001-12-27 University Of Sheffield Antigenic polypeptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ETZ H ET AL: "IDENTIFICATION OF IN VIVO EXPRESSED VACCINE CANDIDATE ANTIGENS FROM STAPHYLOCOCCUS AUREUS", PNAS, vol. 99, no. 10, 14 May 2002 (2002-05-14), pages 6573 - 6578, XP002222373 *
SIOUD M ET AL: "PROFILING THE IMMUNE RESPONSES IN PATIENT SERA WITH PEPTIDE AND CDNA DISPLAY LIBRARIES (REVIEW)", INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, SPANDIDOS, ATHENS, GR, vol. 2, no. 6, 2000, pages 123 - 128, XP001062909, ISSN: 1107-3756 *

Also Published As

Publication number Publication date
AU2003254555A1 (en) 2004-02-23
WO2004013166A2 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
WO2003000906A3 (en) Plant disease resistance genes
WO2000061151A3 (en) Oligodeoxynucleotide and its use to induce an immune response
DE60132474D1 (en) AN IMMUNOSTIMULATING NUCLEOTIDE AND A TOCOL-CONTAINING COMPOSITION
MY137619A (en) 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
MXPA03002453A (en) Use of immidazoquinolinamines as adjuvants in dna vaccination.
WO2002022675A3 (en) Plant genes, the expression of which are altered by pathogen infection
AU6799000A (en) Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or pro-ms immune response
WO2003014079A8 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
WO2003020932A1 (en) Novel secretory proteins and dna thereof
WO2003000186A3 (en) Novel phenylamino-pyrimidines and uses thereof
WO2002045666A3 (en) Novel use of protein hydrolysates
AU2003302235A1 (en) Gp120 specific antigens, conjugates thereof, methods for their preparation and uses thereof
AU2003304180A1 (en) Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
WO2004013166A3 (en) S. aureus antigene
EP1905449A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
CA2406884A1 (en) Novel collectins
HUP0300222A3 (en) Novel lhrh-antagonists, production and use thereof as medicament
ZA200110244B (en) Novel xanthone compounds, their preparation and use as medicament.
WO2004024681A3 (en) Novel compounds comprising a thiocarbonyl-sulfanyl group, which can be used for the radical synthesis of alpha-perfluoroalkylamines
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant
AU2001288236A1 (en) Natural, non-allergenic, immune system stimulant
EP1123695A3 (en) Oral composition comprising capsules containing keratin
MXPA04002104A (en) Antibodies against caspase-8, their preparation and use.
WO2002038803A3 (en) Novel marker for the diagnosis and therapy of tumours

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载